Chenthamarakshan Vasu to CTLA-4 Antigen
This is a "connection" page, showing publications Chenthamarakshan Vasu has written about CTLA-4 Antigen.
Connection Strength
0.753
-
Activation of T cell checkpoint pathways during ?-cell antigen presentation by engineered dendritic cells promotes protection from type 1 diabetes. Immunology. 2022 07; 166(3):341-356.
Score: 0.202
-
Engineered Dendritic Cell-Directed Concurrent Activation of Multiple T cell Inhibitory Pathways Induces Robust Immune Tolerance. Sci Rep. 2019 08 19; 9(1):12065.
Score: 0.168
-
Dendritic cell-directed CTLA-4 engagement during pancreatic beta cell antigen presentation delays type 1 diabetes. J Immunol. 2010 Jun 15; 184(12):6695-708.
Score: 0.088
-
Preferential costimulation by CD80 results in IL-10-dependent TGF-beta1(+) -adaptive regulatory T cell generation. J Immunol. 2008 May 15; 180(10):6566-76.
Score: 0.077
-
Enhanced engagement of CTLA-4 induces antigen-specific CD4+CD25+Foxp3+ and CD4+CD25- TGF-beta 1+ adaptive regulatory T cells. J Immunol. 2007 Oct 15; 179(8):5191-203.
Score: 0.074
-
Targeted CTLA-4 engagement induces CD4+CD25+CTLA-4high T regulatory cells with target (allo)antigen specificity. J Immunol. 2004 Aug 15; 173(4):2866-76.
Score: 0.059
-
Targeted engagement of CTLA-4 prevents autoimmune thyroiditis. Int Immunol. 2003 May; 15(5):641-54.
Score: 0.054
-
A novel pancreatic ?-cell targeting bispecific-antibody (BsAb) can prevent the development of type 1 diabetes in NOD mice. Clin Immunol. 2014 Jul; 153(1):187-98.
Score: 0.029